This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Rubius Therapeutics, Inc. Company Information

Rubius Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

Name: Rubius Therapeutics, Inc.
Ticker: 5RT
Exchange: DB
Founded: 2013
Industry: Biotechnology
Sector: Pharmaceuticals & Biotech
Market Cap: US$1.855m
Listing Market Cap: US$1.727m
Shares Outstanding: 90.48m
Website: https://www.rubiustx.com

Number of Employees

Location

Rubius Therapeutics, Inc.
124 Washington Street
Suite 101
Foxborough
Massachusetts
02035
United States

Listings

Ticker	Exchange	Primary Security	Security Type	Country	Currency	Listed on
RUBY	OTCPK (Pink Sheets LLC)	Yes	Common Stock	US	USD	Jul 2018
5RT	DB (Deutsche Boerse AG)	Yes	Common Stock	DE	EUR	Jul 2018

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
Data	Last Updated (UTC time)
Company Analysis	2023/06/12 12:07
End of Day Share Price	2023/03/15 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/06/12 12:07
End of Day Share Price	2023/03/15 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rubius Therapeutics, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Michael Schmidt	Guggenheim Securities, LLC
Andrew Fein	H.C. Wainwright & Co.
Michael Yee	Jefferies LLC